Literature DB >> 24048416

Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy.

S Koschmieder1, T Burmeister2, M Brüggemann3, A Berkemeier1, S Volpert4, P Wieacker4, G Silling1, N Gökbuget5, C Müller-Tidow1, W E Berdel1, M Stelljes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24048416     DOI： 10.1038/leu.2013.272

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; J Cools; C Melotte; H Quentmeier; A Ferrando; R Levine; J R Vermeesch; M Stul; B Dutta; N Boeckx; A Bosly; P Heimann; A Uyttebroeck; N Mentens; R Somers; R A F MacLeod; H G Drexler; A T Look; D G Gilliland; L Michaux; P Vandenberghe; I Wlodarska; Peter Marynen; Anne Hagemeijer
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

2.  Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.

Authors:  K Stergianou; C Fox; N H Russell
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

3.  NUP214-ABL1 in adult T-ALL: the GMALL study group experience.

Authors:  Thomas Burmeister; Nicola Gökbuget; Richard Reinhardt; Harald Rieder; Dieter Hoelzer; Stefan Schwartz
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

4.  Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; M Stevens-Kroef; M Lafage; N Dastugue; C J Harrison; F Mugneret; K Bahloula; S Struski; M J Grégoire; N Nadal; E Lippert; S Taviaux; A Simons; R P Kuiper; A V Moorman; K Barber; A Bosly; L Michaux; P Vandenberghe; I Lahortiga; K De Keersmaecker; I Wlodarska; J Cools; A Hagemeijer; H A Poirel
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

5.  Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

Authors:  W Deenik; H B Beverloo; S C P A M van der Poel-van de Luytgaarde; M M Wattel; J W J van Esser; P J M Valk; J J Cornelissen
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

6.  NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.

Authors:  Sarah Clarke; John O'Reilly; Giuliana Romeo; Julian Cooney
Journal:  Leuk Res       Date:  2011-04-13       Impact factor: 3.156

7.  Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.

Authors:  Ofelia Crombet; Kelly Lastrapes; Arthur Zieske; Jaime Morales-Arias
Journal:  Pediatr Blood Cancer       Date:  2012-01-03       Impact factor: 3.167

Review 8.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528
  9 in total
  5 in total

1.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

2.  Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

Authors:  Egle Stukaite-Ruibiene; Rimvydas Norvilas; Vaidas Dirse; Sigita Stankeviciene; Goda Elizabeta Vaitkeviciene
Journal:  Pathol Oncol Res       Date:  2022-09-12       Impact factor: 2.874

3.  Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing.

Authors:  Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

4.  Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Authors:  Marlies Vanden Bempt; Sofie Demeyer; Michaël Broux; Jolien De Bie; Simon Bornschein; Nicole Mentens; Roel Vandepoel; Ellen Geerdens; Enrico Radaelli; Beat C Bornhauser; Andreas E Kulozik; Jules P Meijerink; Jean-Pierre Bourquin; Charles E de Bock; Jan Cools
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

Review 5.  The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.

Authors:  Paniz Tavakoli Shirazi; Laura N Eadie; Susan L Heatley; Timothy P Hughes; David T Yeung; Deborah L White
Journal:  Br J Cancer       Date:  2019-12-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.